Two additional Phase I trials (NCT04483778 and NCT04897321) are investigating B7-H3-targeted CAR-T cell therapies in patients with B7-H3-positive solid tumors, also enrolling individuals with NF1-associated MPNST, including bispecific B7-H3xCD19 CAR-T constructs and combination therapy with pembrolizumab to enhance antitumor activity and persistence. This evidence concerns the gene NF1 and malignant peripheral nerve sheath tumor.